To the Editor:Diagnosing Alzheimer’s disease(AD)remains challenging,as clinical diagnostic accuracy is often inferior to neuropathological confirmation.The AT(N)system,introduced by the National Institute on Aging-Al...To the Editor:Diagnosing Alzheimer’s disease(AD)remains challenging,as clinical diagnostic accuracy is often inferior to neuropathological confirmation.The AT(N)system,introduced by the National Institute on Aging-Alzheimer’s Association(NIA-AA),provides a biomarker framework to increase diagnostic precision in AD research.[1]Recent technological innovations,such as ultrasensitive assays like Single Molecule Array(Simoa),have enabled precise evaluation of blood biomarkers,offering potential for noninvasive diagnostics.展开更多
A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer's disease(AD).Recent advancement in ultrasensitive protein assays has...A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer's disease(AD).Recent advancement in ultrasensitive protein assays has allowed the quantification of tau and phosphorylated tau proteins in peripheral plasma.Here we identified 66 eligible studies reporting quantification of plasma tau and phosphorylated tau 181(ptau181)using four ultrasensitive methods.Meta-analysis of these studies confirmed that the AD patients had significantly higher plasma tau and ptau181 levels compared with controls,and that the plasma tau and ptau181 could predict AD with high-accuracy area under curve of the Receiver Operating Characteristic Therefore,plasma tau and plasma ptau181 can be considered as biomarkers for AD diagnosis.展开更多
基金This study was supported by grants from the National Key Research and Development Program of China(Nos.2020YFA0804500 and 2020YFA0804501)CAMS Innovation fund for medical sciences(CIFMS)(Nos.2021-I2M-1-020 and 2020-I2M-C&T-B-010)+1 种基金National Natural Science Foundation of China(Nos.81550021 and 30470618)National High Level Hospital Clinical Research Funding(Nos.2022-PUMCH-D-007 and 2022-PUMCH-A-254).
文摘To the Editor:Diagnosing Alzheimer’s disease(AD)remains challenging,as clinical diagnostic accuracy is often inferior to neuropathological confirmation.The AT(N)system,introduced by the National Institute on Aging-Alzheimer’s Association(NIA-AA),provides a biomarker framework to increase diagnostic precision in AD research.[1]Recent technological innovations,such as ultrasensitive assays like Single Molecule Array(Simoa),have enabled precise evaluation of blood biomarkers,offering potential for noninvasive diagnostics.
基金supported by the Ministry of Science and Technology of China(2018YFC1312300)the National Natural Science Foundation of China(81722016)。
文摘A lack of convenient and reliable biomarkers for diagnosis and prognosis is a common challenge for neurodegenerative diseases such as Alzheimer's disease(AD).Recent advancement in ultrasensitive protein assays has allowed the quantification of tau and phosphorylated tau proteins in peripheral plasma.Here we identified 66 eligible studies reporting quantification of plasma tau and phosphorylated tau 181(ptau181)using four ultrasensitive methods.Meta-analysis of these studies confirmed that the AD patients had significantly higher plasma tau and ptau181 levels compared with controls,and that the plasma tau and ptau181 could predict AD with high-accuracy area under curve of the Receiver Operating Characteristic Therefore,plasma tau and plasma ptau181 can be considered as biomarkers for AD diagnosis.
